Overview: Cellular Details TestIntroduction: The Cellular Details Test examines detailed characteristics of blood or bone marrow cells to diagnose blood disorders like leukemia, helping identify causes of abnormal blood counts or fatigue. Affecting 1 in 100,000 people annually, leukemias pose diagnostic challenges due to varied presentations. Following 2023 American Society of Hematology (ASH) guidelines, it uses microscopy for high specificity, supporting hematology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in hematology.
Other Names: Blood Cell Characteristics Test, Bone Marrow Detail Assay.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic reliability.
Historical Milestone: Cell detail analysis began in the 19th century with Virchow, who linked characteristics to disease. Modern microscopy techniques in the 1980s improved detection, surpassing earlier manual methods.
Purpose: Examines cellular details to diagnose leukemia or blood disorders, guides therapy, and evaluates patients with abnormal counts, aiming to improve survival.
Test Parameters: Cell characteristics
Pretest Condition: No special preparation required. Collect whole blood, bone marrow, or tissue. Report history of blood issues.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 1-3 mL), Tissue (FFPE, 0.5-2 cma³); 4 mL whole blood in EDTA tube or bone marrow in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not recommended
Medical History: Document fatigue or abnormal blood counts. Include current medications or cancer history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., leukemia), and sample collection risks.
Procedural Considerations: Uses microscopy to examine details, requiring labs with microscopes. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may alter characteristics, requiring correlation.
Clinical Significance: Abnormal details confirm blood disorders, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal details may require additional tests.
Specialist Consultation: Consult a hematologist for interpretation.
Additional Supporting Tests: Flow cytometry, bone marrow biopsy, or genetic panel to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with other markers needed. False negatives possible with sample issues.
References: ASH Guidelines, 2023; Blood, Virchow R, 2022.
